Answers are grounded in this paper and cite their sources.
This article provides an overview of the causes and mechanisms of drug hyperprolactinemia (GP) associated with the use of antipsychotics, and describes its main clinical symptoms. The most probable factors of the high frequency of GP development that persists to date when using antipsychotics in the practice of a psychiatrist are considered. Modern methods of its prevention and correction developed by domestic and foreign researchers are presented. Emphasis is placed on the importance and necessity of careful collection of the patient's medical history, laboratory and instrumental examination, monitoring of the dynamics of hormonal indicators, correct choice of therapeutic tactics for the prevention of GP and its timely relief. The neuroendocrine profile of the latest generation of antipsychotics is considered. Special attention is paid to the partial agonist of D-2, D3-dopamine receptors cariprazine. Based on the review of recent clinical studies, the possibilities of its use in clinical practice are considered in detail, and the neuroendocrine profile of the drug is presented. The prospects of its use as a corrector of GP associated with the treatment of mental disorders with other antipsychotics are evaluated.
No takes yet. Share an insight, caveat, or question.
DOROVSKIKH et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: